Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | PLAT | P00750 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 6/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351945 | 1.00 | PLG (0.50) | PLGPLATLMNAEPHX2NCF1 | |
| SCHEMBL5046197 | 1.00 | PLG (0.50) | PLGPLATLMNAEPHX2NCF1 | |
| Hydrochloric Acid SCHEMBL7415651 | 0.97 | PLG (0.48) | PLGPLATLMNAEPHX2NCF1 | |
| Hydrochloric Acid SCHEMBL7415656 | 0.97 | PLG (0.48) | PLGPLATLMNAEPHX2NCF1 | |
| Monoethanolamine SCHEMBL10958862 | 0.92 | PLG (0.44) | PLGPLATLMNAEPHX2NCF1 | |
| Hydrazine SCHEMBL1873192 | 0.83 | ESR1 (0.42) | PLGPLATLMNAEPHX2ESR1 | |
| SCHEMBL1703765 | 0.83 | PLG (0.55) | PLGPLATLMNAEPHX2NCF1 | |
| SCHEMBL48375 | 0.83 | PLG (0.55) | PLGPLATLMNAEPHX2NCF1 | |
| SCHEMBL6802 | 0.83 | — | — | |
| SCHEMBL432248 | 0.83 | PLG (0.55) | PLGPLATLMNAEPHX2NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019063748-A1 | ROR-GAMMA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-04 | — | — | WO | disclosed |
| WO-2019063748-A1 | ROR-GAMMA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-04 | — | — | WO | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| EP-1716100-A2 | THERAPEUTIC AMIDE DERIVATIVES | Pfizer, Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | PLG 2223/4885PLAT 4798/4885LMNA 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.